[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"steroid-refractory-acute-graft-versus-host-diseasesr-agvhd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:steroid-refractory-acute-graft-versus-host-diseasesr-agvhd":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100540773","a-trial-to-evaluate-the-safety-and-preliminary-efficacy-of-imesenchymal-stromal-cellsimsc-in-subjects-with-sr-agvhd-100540773",false,"NCT06321198","A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD","A Trial to Evaluate the Safety and Preliminary Efficacy of Human Induced Pluripotent Stem Cell Derived Mesenchymal Stromal Cells in Subjects With Steroid-refractory Acute Graft-Versus-Host Disease","Inclusion Criteria:\n\n1.Subjects who understand and voluntarily sign the Informed Consent Form(ICF); 2.4-70 years; 3.Subjects with SR-aGVHD; 4.ECOG≤2; 5.Subjects with II to IV grades of steroid hormone resistance;\n\nExclusion Criteria:\n\n1. Accepted systemic or local treatment of mesenchymal stem cells;\n2. Have severe allergy to blood products or have allergy history of heterologous protein;\n3. Expected survival period within 3 months;\n4. Alanine transaminase(ALT)or Aspartate aminotransferase(AST)\\>2\\*upper limit of normal(ULN);Creatinine clearance rate≤30ml\u002Fmin or Blood Urea Nitrogen(BUN)\\>2\\*upper limit of normal(ULN), International Normalized Ratio (INR)\\>1.5\\*upper limit of normal(ULN);\n5. Have severe hepatic veno-occlusive disease(HVOD);\n6. Have severe lung disease like severe lung infection;\n7. Have history of severe acute myocardial infarction or have uncontrolled angina pectoris,arrhythmia and severe heart failure;\n8. Proved having resistant hypertension within 6 months before enrollment;\n9. Have active thrombus;\n10. Have untreated or uncertain active solid tumors within 5 years;\n11. Have alcohol or drug addiction or with a clear history of mental disorders or with a history of drug abuse or drug use of psychotropic substances;\n12. Human immunodeficiency virus(HIV)antibody positive, treponema pallidum (TP) antibody positive;\n13. Have active hepatitis B or hepatitis C;\n14. Have gastrointestinal symptoms which not caused by GVHD\n15. Pregnant or lactating female subjects, or subjects who are unable to comply with contraceptives from the study period to 6 months after the end of this study;\n16. Subjects who have participated in other clinical trials and have used other study products within 12 weeks before screening;\n17. Not suitable for this clinical trial for other reasons.","ALL","4 Years","70 Years",{"count":20,"type":21},12,"ESTIMATED","INTERVENTIONAL",[24],"NA","A study to evaluate the safety and preliminary efficacy of iMSC in subjects with SR-aGVHD",[27],"Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)","RECRUITING","2026-03-24",{"date":31,"type":32},"2026-03-27","ACTUAL",{"date":34,"type":32},"2024-02-10",{"date":36,"type":21},"2027-03-02",{"name":38,"class":39},"Anhui Provincial Hospital","OTHER_GOV"]